The Human Hepatic Cytochromes P450 Involved in Drug Metabolism

References

• Nebert D. W., Nelson D. R., Coon M. J., Estabrook R. W., Feyerseisen R., Pujii-Kuriyama Y., Gonzalez F. J., Guengerich F. P., Gunsalus I. C., Johnson E. F., Loper J. C., Sato R., Waterman M. R., Waxman D. J. The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA Cell. Biol. 1991; 10: 1
   PubMed Web of Science ®Google Scholar
• Guengerich F. P. Enzymatic oxidation of xeno-biotic chemicals. Biochem. Mol. Biol. 1990; 25: 97
   Google Scholar
• Nebert D. W., Jaiswal A. K., Meyer U. A., Gonzalez F. J. Human P-450 genes: evolution, regulation and possible role in carcinogenesis. Biochem. Soc. Trans. 1987; 15: 586
   PubMedGoogle Scholar
• Guengerich F. P. Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy. Cancer Res. 2946; 48: 1988
   Google Scholar
• Ryan D. E., Levin W. Purification and characterization of hepatic microsomal cytochrome P-450. Pharmacol. Ther. 1990; 45: 153
   PubMed Web of Science ®Google Scholar
• Riviere J. L., Cabanne F. Animal and plant cytochrome P-450 systems. Biochimie 1987; 69: 743
   PubMedGoogle Scholar
• Sariaslani F. S. Microbial cytochromes P-450 and xenobiotic metabolism. Adv. Appl. Microbiol. 1991; 36: 133
   PubMed Web of Science ®Google Scholar
• Guengerich F. P. Characterization of human microsomal cytochrome P-450 enzymes. Annu. Rev. Pharmacol. Toxicol. 1989; 29: 241
   PubMed Web of Science ®Google Scholar
• Shimada T., Guengerich F. P. Participation of a rat liver cytochrome P-450 induced by pregnenolone 16a-carbonitrile and other compounds in the 4-hydroxylation of mephenytoin. Mol. Pharmacol. 1985; 28: 215
   PubMed Web of Science ®Google Scholar
• Brian W. R., Srivastava P. K., Umbenhauer D. R., Lloyd R. S., Guengerich F. P. Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in. Sac-charomyces cerevisiae. Biochemistry 4993; 28: 1989
   Google Scholar
• Gonzalez F. J. The molecular biology of cytochrome P450s. Pharmacol. Rev. 1989; 40: 243
   Web of Science ®Google Scholar
• Nebert D. W. P450 genes: structure, evolution, and regulation. Annu. Rev. Biochem. 1987; 56: 945
   PubMed Web of Science ®Google Scholar
• Smith D. A. Species differences in metabolism and pharmacokinetics: are we close to an understanding?. Drug Metab. Rev. 1991; 23: 355
   PubMed Web of Science ®Google Scholar
• Gonzalez F. J. The molecular biology of cytochrome P450s. Pharmacol. Rev. 1988; 40: 243
   PubMed Web of Science ®Google Scholar
• Jaiswal A. K., Gonzalez F. J., Nebert D. W. Human dioxin-inducible cytochrome P.-450: complementary DNA and amino acid sequence. Science 1985; 228: 80
   PubMed Web of Science ®Google Scholar
• Quattrochi L. C., Pendurthi U. R., Okino S. T., Potenza C., Tukey R. H. Human cytochrome P-450 4 mRNA and gene: part of a multigene family that containsAlu sequences in its mRNA. Proc. Natl. Acad. Sci. U.S.A. 1986; 83: 6731
   PubMed Web of Science ®Google Scholar
• Sogawa K., Fujisawa-Sehara A., Yamane M., Fujii-Kuriyama Y. Localization of regulator elements responsible for drug induction in the rat cytochrome P-450c gene. Proc. Natl. Acad. Sci. U.S.A. 1986; 83: 8044
   PubMed Web of Science ®Google Scholar
• Conney A. H., Gillette J. R., Inscoe J. K., Frams E. R., Posner H. S. Induced synthesis of liver microsomal enzymes which metabolize foreign compounds. Science 1959; 130: 1478
   PubMed Web of Science ®Google Scholar
• Nebert D. W., Jones J. J. Regulation of the mammalian cytochrome P. 450 (CYP1A1) gene. Int. J. Biochem. 1989; 21: 243
   PubMedGoogle Scholar
• Whitlock J. P. The regulation of gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Pharmacol. Rev. 1987; 39: 147
   PubMed Web of Science ®Google Scholar
• Wrighton S. A., Campanile C., Thomas P. E., Maines S. L., Watkins P. B., Parker G., Mendez-Picon G., Haniu M., Shively J., Levin W., Guzelian P. S. Identification of a human liver cytochrome P-450 homologous to the major iso-safrole-inducible cytochrome P-450 in the rat. Mol. Pharmacol. 1986; 29: 405
   PubMed Web of Science ®Google Scholar
• Quattrochi L. C., Tukey R. H. The human cytochrome CyplA2 gene contains regulatory elements responsive to 3-methylcholanthrene. Mol. Pharmacol. 1989; 36: 66
   PubMed Web of Science ®Google Scholar
• Pasanen M., Stenback F., Park S. S., Gelboin H. V., Pelkonen O. Immunohistochemical detection of human placental cytochrome P-450-asso-ciated mono-oxygenase systeminducible by maternal cigarette smoking. Placenta 1988; 9: 267
   PubMed Web of Science ®Google Scholar
• Kawajiri K., Nakachi K., Imai K., Yoshii A., Shinoda N., Watanabe J. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P4501A1 gene. FEBS Lett. 1990; 263: 131
   PubMed Web of Science ®Google Scholar
• Petersen D. D., McKinney C. E., Ikeya K., Smith H. H., Bale A. E., McBride O. W., Nebert D. W. Human CYP1A1 gene: cosegrega-tion of the enzyme inducibility phenotype and an RFLP. Am. J. Hum. Genet. 1991; 48: 720
   PubMed Web of Science ®Google Scholar
• Disterlath L. M., Reilly P. E.B., Martin M. V., Davis G. G., Wilkinson S. G., Guengerich F. P. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 1985; 260: 9057
   PubMedGoogle Scholar
• Butler M. A., Iwasaki M., Guengerich F. P., Kadlubar F. F. Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primary responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc. Natl. Acad. Sci. U.S.A. 1989; 86: 7696
   PubMed Web of Science ®Google Scholar
• Guengerich F. P., Turvy C. G. Comparison levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal disease states using immunochemical analysis of surgical liver samples. J. Pharmacol. Exp. Ther. 1991; 256: 1189
   PubMed Web of Science ®Google Scholar
• Kalow W., Tang B. K. Caffeine as a metabolite probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin. Pharmacol. Ther. 1991; 49: 44
   PubMed Web of Science ®Google Scholar
• Sesardic D., Boobis A. R., Edwards R. J., Davies D. S. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br. J. Clin. Pharmacol. 1988; 26: 363
   PubMed Web of Science ®Google Scholar
• Boobis A. R., Davies D. S. Human cytochromes P-450. Xenobiotica 1984; 14: 151
   PubMed Web of Science ®Google Scholar
• Vistisen K., Loft S., Poulsen H. E. Cytochrome P450 IA2 activity in man measured by caffeine metabolism: effect of smoking, broccoli, and exercise, in. Biological Reactive Intermediates IV: Molecular and Cellular Effects and Their Impact on Human Health, C Witmer, R. Snyder, D. Jollow, G. Kalf, J. Kocsis, I. Sipes. Plenum Press, New York 1991; vol. 283: 407, s
   Google Scholar
• Diaz D., Fabre I., Daujat M., Saint Aubert B., Bories P., Michel H., Maurel P. Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology 1990; 99: 737
   PubMed Web of Science ®Google Scholar
• Anderson T., Bergstrand R., Cederberg C., Lagerstrom P. O., Skanberg I. Omeprazole treatment does not affect the metabolism of caffeine. Gastroenterology 1991; 101: 943
   PubMedGoogle Scholar
• Michnovicz J. J., Bradlow H. L. Induction of estradiol metabolism by dietary indole-3-carbinol in humans. JNCI 1990; 82: 947
   PubMed Web of Science ®Google Scholar
• Michnovicz J. J., Bradlow H. L. Altered estrogen metabolism and excretion in humans following consumption of indole-3-carbinol. Nutr. Cancer 1991; 16: 59
   PubMed Web of Science ®Google Scholar
• Watkins P. B., Murray S. A., Thomas P. E., Wrighton S. A. Distribution of cytochromes P-450, cytochrome b5, and NADPH-cytochrome P-450 reductase in an entire human liver. Biochem. Pharmacol. 1990; 39: 471
   PubMed Web of Science ®Google Scholar
• Sesardic D., Boobis A. R., Murray B. P., Murray S., Segura J., De La Torre R., Davies D. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br. J. Clin. Pharmacol. 1990; 29: 651
   PubMed Web of Science ®Google Scholar
• Ryan D. E., Thomas P. E., Korzeniowski D., Levin W. Separation and characterization of highly purified forms of liver microsomal cytochrome P-450 from rats treated with polychlorinated biphen-yls, phenobarbital, and 3-methylcholanthrene. J. Biol. Chem. 1979; 254: 1365
   PubMed Web of Science ®Google Scholar
• Arlotto M. P., Greenway D. J., Parkinson A. Purification of two isozymes of rat liver microsomal cytochrome P450 with testosterone 7a-hy-droxylation activity. Arch. Biochem. Biophys. 1989; 270: 441
   PubMed Web of Science ®Google Scholar
• Kimura S., Kozak C. A., Gonzalez F. J. Identification of a novel P450 expressed in rat lung: cDNA cloning and sequence, chromosome mapping, and induction by 3-methylcholanthrene. Biochemistry 1989; 28: 3798
   PubMed Web of Science ®Google Scholar
• Lindberg R., Burkhart B., Ichikawa T., Negishi M. The structure and characterization of type I P-450,15α gene as major steroid 15ot-hydroxylase and its comparison with type II P-45015n gene. J. Biol. Chem. 1989; 264: 6465
   PubMed Web of Science ®Google Scholar
• Burkhart B. A., Skow L. C., Negishi M. Two steroid 15a-hydroxylase genes and a homologous gene family in mice. Gene 1990; 87: 205
   PubMedGoogle Scholar
• Harada N., Negishi M. Mouse liver testosterone 15a-hydroxylase (cytochrome P-450,15α). J. Biol. Chem. 1984; 259: 1265
   PubMedGoogle Scholar
• Negishi M., Lindberg R., Burkhart B., Ichikawa T., Honkakoski P., Lang M. Mouse steroid 15α -hydroxylase gene family: identification of type II P-450,15α as coumarin 7-hydrox-ylase. Biochemistry 1989; 28: 4169
   PubMed Web of Science ®Google Scholar
• Aida K., Negishi M. Posttranscriptional regulation of coumarin 7-hydroxylase induction by xe-nobiotics in mouse liver: mRNA stabilization by pyr-azole. Biochemistry 1991; 30: 8041
   PubMed Web of Science ®Google Scholar
• Wrighton S. A., Ring B. J., Watkins P. B., VandenBranden M. Identification of a polymorph-ically expressed member of the human cytochrome P-450III family. Mol. Pharmacol. 1989; 36: 97
   PubMed Web of Science ®Google Scholar
• Raunio H., Syngelma T., Pasanen M., Juvonen R., Honkakoski P., Kairaluoma M. A., Sotaniemi E., Lange M. A., Pelkonen O. Immunochemical and catalytical studies on hepatic coumarin 7-hydroxylase in man, rat, and mouse. Biochem. Pharmacol. 1988; 37: 3889
   PubMed Web of Science ®Google Scholar
• Yamano S., Tatsuno J., Gonzalez F. J. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 1990; 29: 1322
   PubMed Web of Science ®Google Scholar
• Yun C. H., Shimada T., Guengerich F. P. Purification and characterization of human liver microsomal cytochrome P-450 2A6. Mol. Pharmacol. 1991; 40: 679
   PubMed Web of Science ®Google Scholar
• Wrighton S. A., VandenBranden M., Becker G. W., Black S. D., Thomas P. E. Two monoclonal antibodies recognizing different epitopes on rat cytochrome IIB1 react with human IIE1. Mol. Pharmacol. 1992; 41: 76
   PubMed Web of Science ®Google Scholar
• Wrighton S. A., Thomas P. E., Ryan D. E., Levin W. Purification and characterization of ethanol-inducible human hepatic cytochrome P-450HLJ. Arch. Biochem. Biophys. 1987; 258: 292
   PubMed Web of Science ®Google Scholar
• Waxman D. J., Lapenson D. P., Aoyama T., Gelboin H. V., Gonzalez F. J., Korzekwa K. Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch. Biochem. Biophys. 1991; 290: 160
   PubMed Web of Science ®Google Scholar
• Adesnik M., Atchison M. Genes for cytochrome P-450 and their regulation. Crit. Rev. Biochem. 1985; 19: 247
   Google Scholar
• Guengerich F. P., Dannan G. A., Wright S. T., Martin M. V., Kaminsky L. S. Purification and characterization of liver microsomal cytochromes P-450: electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or B-naphthoflavone. Biochemistry 1982; 21: 6019
   PubMed Web of Science ®Google Scholar
• Adams D. J., Seilman S., Amelizad Z., Oesch F., Wolf C. R. Identification of human cytochromes P-450 analogous to forms induced by phenobarbital and 3-methylcholanthrene in the rat. Biochem. J. 1985; 232: 869
   PubMed Web of Science ®Google Scholar
• Fujino T., Park S. S., West D., Gelboin H. V. Phenotyping of cytochromes P-450 in human tissues with monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A. 1982; 79: 3682
   PubMed Web of Science ®Google Scholar
• Yamano S., Nhamburo P. T., Aoyama T., Meyer U. A., Inaba T., Kalow W., Gelboin H. V., McBride O. W., Gonzalez F. J. cDNA cloning and sequence and cDNA-directed expression of human P450 IIB1: identification of a normal and two variant cDNAs derived from the CYP2B locus on chromosome 19 and differential expression of the IIB mRNAs in human liver. Biochemistry 1989; 28: 7340
   PubMed Web of Science ®Google Scholar
• Miles J. S., Spurr N. K., Gough A. C., Jowett T., McLaren A. W., Brook J. D., Wolf C. R. A novel human cytochrome P450 gene (P450IIB): chromosomal localization and evidence for alternative splicing. Nucleic Acids Res. 1988; 16: 5783
   PubMed Web of Science ®Google Scholar
• Ged C., Umbenhauer D. R., Bellew T. M., Bork R. W., Srivastava P. K., Shinriki N., Lloyd R. S., Guengerich F. P. Characterization of cDNAs, mRNAs, and proteins related to human liver microsomal cytochrome P-450 (S)-mephenytoin 4′-hydroxylase. Biochemistry 1988; 27: 6929
   PubMed Web of Science ®Google Scholar
• Dieter H. H., Miiller-Eberhard U., Johnson E. F. Identification of rabbit microsomal cytochrome P-450 isozyme, form 1, as a hepatic progesterone 21-hydroxylase. Biochem. Biophys. Res. Commun. 1982; 105(2)515
   PubMedGoogle Scholar
• Okino S. T., Quattrochi L. C., Pendurthi U. R., McBride O. W., Tukey R. H. Characterization of multiple human cytochrome P-450 1 cDNAs. J. Biol. Chem. 1987; 262: 16072
   PubMed Web of Science ®Google Scholar
• Wrighton S. A., Thomas P. E., Willis P., Maines S. L., Watkins P. B., Levin W., Guzelian P. S. Purification of a human liver cytochrome P-450 immunochemically related to several cytochromes P-450 purified from untreated rats. J. Clin. Invest. 1987; 80: 1017
   PubMed Web of Science ®Google Scholar
• Leo M. A., Lasker J. M., Raucy J. L., Kim C. I., Black M., Lieber C. S. Metabolism of retinal and retinoic acid by human liver cytochrome P450IIC8. Arch. Biochem. Biophys. 1989; 269: 305
   PubMed Web of Science ®Google Scholar
• Romkes M., Faletto M. B., Blaisdell J. A., Raucy J. L., Goldstein J. A. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 1991; 30: 3247
   PubMed Web of Science ®Google Scholar
• Shimada T., Misono K. S., Guengerich F. P. Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 1986; 261: 909
   PubMed Web of Science ®Google Scholar
• Yasumori T., Murayama N., Yamazoe Y., Abe A., Nogi Y., Fukasawa T., andKato R. Expression of a human P-450IIC gene in yeast cells using galactose-inducible expression system. Mol. Pharmacol. 1989; 35: 443
   PubMed Web of Science ®Google Scholar
• Relling M. V., Aoyama T., Gonzalez F. J., Meyer U. A. Tolbutamide and mephenytoin hy-droxylation by human cytochrome P450s in the CYP2C subfamily. J. Pharm. Exp. Ther. 1989; 252: 442
   Web of Science ®Google Scholar
• Srivastava P. K., Yun C. H., Beaune P. H., Ged C., Guengerich F. P. Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4′-hydroxylase cytochrome P-450 enzymes. Mol. Pharmacol. 1991; 40: 69
   PubMed Web of Science ®Google Scholar
• Back D. J., Tjia J. F., Karbwang J., Colbert J. In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, suphonamides and quinolines. Br. J. Clin. Pharmacol. 1988; 26: 23
   PubMed Web of Science ®Google Scholar
• Miners J. O., Smith K. J., Robson R. A., McManus M. E., Veronese M. E., Birkett D. J. Tolbutamide hydroxylation by human liver microsomes. Biochem. Pharmacol. 1988; 37: 1137
   PubMed Web of Science ®Google Scholar
• Homberg J. C., Andre C., Abuaf N. A new anti-liver-kidney microsome antibody (anti-LKM2) in tienilic acid-induced hepatitis. Clin. Exp. Immunol. 1984; 55: 561
   PubMed Web of Science ®Google Scholar
• Beaune P., Dansette P. M., Mansuy D., Kiffel L., Finck M., Amar C., Leroux J. P., Homberg J. C. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc. Natl. Acad. Sci. U.S.A. 1987; 84: 551
   PubMed Web of Science ®Google Scholar
• Meier U. T., Meyer U. A. Genetic polymorphism of human cytochrome P-450 (S)-mephen-ytoin 4-hydroxylase. Studies with human autoantibodies suggest a functionally altered cytochrome P-450 isozyme as cause of the genetic deficiency. Biochemistry 1987; 26: 8466
   PubMed Web of Science ®Google Scholar
• Kalow W. Genetics of drug transformation. Clin. Biochem. 1986; 19: 76
   PubMedGoogle Scholar
• Guengerich F. P. Polymorphism of cytochrome P-450 in humans. TiPS 1989; 10: 107
   PubMed Web of Science ®Google Scholar
• Relling M. V. Polymorphic drug metabolism. Clin. Pharm. 1989; 8: 852
   PubMedGoogle Scholar
• Meyer U. A., Zanger U. M., Grant D., Blum M. Genetic polymorphisms of drug metabolism. Adv. Drug Res. 1990; 19: 198
   Google Scholar
• Helsby N. A., Ward S. A., Howells R. E., Breckenridge A. M. In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme. Br. J. Clin. Pharmacol. 1990; 30: 287
   PubMed Web of Science ®Google Scholar
• Wedlund P. J., Sweetman B. J., Wilkinson G. R., Branch R. A. Pharmacogenetic association between the formation of 4-hydroxyme-phenytoin and a new metabolite of S-mephenytoin in man. Drug Metab. Dispos. 1987; 15: 277
   PubMedGoogle Scholar
• Zhou H. H., Anthony L. B., Wood A. J.J., Wilkinson G. R. Induction of polymorphic 4′-hydroxylation of S-mephenytoin by rifampicin. Br. J. Clin. Pharmacol 1990; 30: 471
   PubMed Web of Science ®Google Scholar
• Jurima M., Inaba T., Kalow W. Mephenytoin hydroxylase activity in human liver: inhibition by steroids. Drug Metab. Dispos. 1985; 13: 746
   PubMedGoogle Scholar
• Mahgoub A., Dring L. G., Idle J. R., Lancaster R., Smith R. L. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2: 584
   PubMed Web of Science ®Google Scholar
• Evans D. P., Mahgoub A., Sloan T. P., Idle J. R., Smith R. L. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J. Med. Genet. 1980; 17: 102
   PubMed Web of Science ®Google Scholar
• Nakamura K., Goto F., Ray W. A., McAllister C. B., Jacqz E. Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin. Pharmacol. Ther. 1987; 38: 402
   Google Scholar
• Larrey D., Disterlath L. M., Dannan G. A., Wilkinson G. R., Guengerich F. P. Purification and characterization of the rat microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism. Biochemistry 1984; 23: 2787
   PubMed Web of Science ®Google Scholar
• Disterlath L. M., Guengerich F. P. Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme. Proc. Natl. Acad. Sci. U.S.A. 1984; 81: 7348
   PubMedGoogle Scholar
• Zanger U. M., Vilbois F., Hardwick J., Meyer U. A. Absence of hepatic cytochrome P450bufl causes genetically deficient debrisoquine oxidation in man. Biochemistry 1988; 27: 5447
   PubMed Web of Science ®Google Scholar
• Gonzalez F. J., Vibois F., Hardwick J. P., McBride O. W., Nebert D. W., Gelboin H. V., Meyer U. A. Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of CYP2D locus to chromosome 22. Genomics 1988; 2: 174
   PubMedGoogle Scholar
• Gonzalez F. J., Skoda R., Kimura S., Umeno M., Zanger U. M., Nebert D. W., Gelboin H. V., Hardwick J. P., Meyer U. A. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988; 331: 442
   PubMed Web of Science ®Google Scholar
• Kagimoto M., Heim M., Kagimoto K., Zeugin T., Meyer U. A. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine: study of the functional significance of individual mutations by expression of chimeric genes. J. Biol. Chem. 1990; 265: 17209
   PubMed Web of Science ®Google Scholar
• Broly F., Gaedigk A., Heim M., Eichelbaum M., Morike K., Meyer U. A. Debrisoquine/ sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol. 1991; 10: 545
   PubMed Web of Science ®Google Scholar
• Lindberg R. L.P., Negishi M. Alteration of mouse cytochrome P450coh substrate specificity by mutation of a single amino acid sequence. Nature 1989; 339: 6226
   Google Scholar
• Kronbach T., Larabee T. M., Johnson E. F. Hybrid cytochromes P-450 identify a substrate binding domain in P-450IIC5 and P-450IIC4. Proc. Natl. Acad. Sci. U.S.A. 1989; 86: 8262
   PubMed Web of Science ®Google Scholar
• Skoda R. C., Gonzalez F. J., Demierre A., Meyer U. A. Two mutant alleles of the human cytochrome P-450dbl gene (P4502D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc. Natl. Acad. Sci. U.S.A. 1988; 85: 5240
   PubMed Web of Science ®Google Scholar
• Meyer U. A. Genetic polymorphisms of drug metabolism. Fund. Clin. Pharmacol. 1990; 4: 595
   PubMed Web of Science ®Google Scholar
• Heim M., Meyer U. A. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 1990; 336: 529
   PubMed Web of Science ®Google Scholar
• Balant L. P., Gundert-Remy U., Boobis A. R., van Bahr C. Relevance of genetic polymorphism in drug metabolism in the development of new drugs. Eur. J. Clin. Pharmacol. 1989; 36: 551
   PubMed Web of Science ®Google Scholar
• Brosen K., Gram L. F. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur. J. Clin. Pharmacol. 1989; 36: 537
   PubMed Web of Science ®Google Scholar
• Dahlstrom B., Paalzow L. Pharmacokinetics and analgesia of codeine and its metabolite morphine, in. Opiates and Endogenous Opioid Peptides, H. W. Kos-terlitz. North Holland, Amsterdam 1976; 395
   Google Scholar
• Desmeules J., Dayer P., Gascon M. P., Magistris M. Impact of genetic and environmental factors in codeine analgesia [Abstr.]. Clin. Pharmacol. Ther. 1989; 45: 122
   Google Scholar
• Dayer P., Desmeules J., Leeman T., Striberni R. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydrox-ylation (cytochrome P-450dbl/bufl). Biochem. Bio-phys. Res. Commun. 1988; 152: 411
   PubMed Web of Science ®Google Scholar
• Yue Q. Y., Svenson J. O., Aim C., Sjoqvist F., Sawe J. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. Br. J. Clin. Pharmacol. 1989; 28: 639
   PubMed Web of Science ®Google Scholar
• Mortimer O., Person K., Landona M. G., Spalding D., Zanger U. M., Meyer U. A., Rane A. Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: relationship to the presence of im-munoidentified cytochrome P-450IID1. Clin. Pharmacol. Ther. 1990; 47: 27
   PubMed Web of Science ®Google Scholar
• Sindrup S. H., Brosen K., Bjerring P., Arendt-Nielsen L., Larsen U., Angelo H. R., Gram L. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clin. Pharmacol. Ther. 1990; 48: 686
   PubMed Web of Science ®Google Scholar
• Barbeau A., Roy M., Paris S., Cloutier T., Plasse L., Poirier J. The ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet 1985; 1213
   Google Scholar
• Baer A. N., McAllister C. B., Wilkinson G. R., Woosley R. I., Pincus T. Altered distribution of debrisoquine oxidation phenotypes in patients with systemic lupus erythematosus. Arthritis Rheum. 1986; 29: 137
   Google Scholar
• Ayesh R., Idle J. R., Ritchie J. C., Crothers M. J., Hetzel M. R. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 1984; 312: 169
   PubMed Web of Science ®Google Scholar
• Caporaso N., Hayes R. B., Dosemeci M., Hoover R., Ayesh R., Hetzel M., Idle J. R. Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype. Cancer Res. 1989; 49: 3675
   PubMed Web of Science ®Google Scholar
• Law M. R., Hetzel M. R., Idle M. R. Debrisoquine metabolism and genetic predisposition to cancer. Br. J. Cancer 1989; 59: 686
   PubMed Web of Science ®Google Scholar
• Harris C. C. Interindividual variation among humans in carcinogen metabolism, DNA adduct formation and DNA repair. Carcinogenesis 1527; 11: 1990
   Google Scholar
• Speirs C. J., Murray S., Davies D. S., Biola Mabadeje A. F., Boobis A. R. Debrisoquine oxidation phenotype and susceptibility to lung cancer. Br. J. Clin. Pharmacol. 1990; 29: 101
   PubMed Web of Science ®Google Scholar
• Sugimura H., Caporaso N. E., Shaw G. L., Modali R. V., Gonzalez F. J., Hoover R. N., Resau J. H., Trump B. F., Weston A., Harris C. C. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls. Carcinogenesis 1990; 11: 1527
   PubMed Web of Science ®Google Scholar
• Zanger U. M., Hauri H. P., Loeper J., Homberg J. C., Meyer U. A. Antibodies against human cytochrome P-450dbl in autoimmune hepatitis type II. Proc. Natl. Acad. Sci. U.S.A. 1988; 85: 8256
   PubMed Web of Science ®Google Scholar
• Manns M. P., Johnson E. F., Griffin K. J., Tan E. M., Sullivan K. F. Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450dbl. J. Clin. Invest. 1989; 83: 1066
   PubMed Web of Science ®Google Scholar
• Leeman T., Dayer P., Meyer U. A. Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers. Eur. J. Clin. Pharmacol. 1986; 29: 739
   PubMedGoogle Scholar
• Yang C. S., Yoo J. S.H., Ishizaki H., Hong J. Cytochrome P450IIE1: roles in nitrosa-mine metabolism and mechanisms of regulation. Drug Metab. Rev. 1990; 22: 147
   PubMed Web of Science ®Google Scholar
• Ryan D. E., Ramanathan L., Iida S., Thomas P. E., Haniu M., Shively J. E., Lieber C. S., Levin W. Characterization of a major form of rat hepatic microsomal cytochrome P-450 induced by isoniazid. J. Biol. Chem. 1985; 260: 6385
   PubMed Web of Science ®Google Scholar
• Patten C. J., Ning S. M., Lu A. Y.H., Yang C. S. Acetone-inducible cytochrome P-450: purification, catalytic activity, and interaction with cytochrome b5. Arch. Biochem. Biophys. 1986; 251: 629
   PubMed Web of Science ®Google Scholar
• Wrighton S. A., Thomas P. E., Molowa D. T., Haniu M., Shively J. E., Maines S. L., Watkins P. B., Parker G., Mendez-Picon G., Levin W., Guzelian P. S. Characterization of ethanol-inducible human liver N-nitrosodimethylamine de-methylase. Biochemistry 1986; 25: 6731
   PubMed Web of Science ®Google Scholar
• Lasker J. M., Raucy J., Kubota S., Bloswick B. P., Black M., Lieber C. S. Purification and characterization of human liver cytochrome P-450-ALC. Biochem. Biophys. Res. Commun. 1987; 148: 232
   PubMed Web of Science ®Google Scholar
• Ekstrom G., von Bahr C., Ingelman-Sundberg M. Human liver microsomal cytochrome P-450IIE1. Immunological evaluation of its contribution to microsomal ethanol oxidation, carbon tetrachloride reduction and NADPH oxidase activity. Biochem. Pharmacol 1989; 38: 689
   PubMed Web of Science ®Google Scholar
• Raucy J. L., Lasker J. M., Lieber C. S., Black M. Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2. Arch. Biochem. Biophys. 1989; 271: 270
   PubMed Web of Science ®Google Scholar
• Guengerich F. P., Kim D. H., Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol. 1991; 4: 168
   PubMed Web of Science ®Google Scholar
• Peter R., Bocker R., Beaune P. H., Iwasaki M., Guengerich F. P., Yang C. S. Hydrox-ylation of chlorzoxazone as a specific probe for human liver cytochrome P-450HE1. Chem. Res. Toxicol. 1990; 3: 566
   PubMed Web of Science ®Google Scholar
• Tinel M., Belghiti J., Descatoire V., Amouyal G., Letteron P., Geneve J., Larrey D., Pessayre D. Inactivation of human liver cytochrome P-450 by the drug methoxsalen and other psoralen derivatives. Biochem. Pharmacol. 1987; 36: 951
   PubMed Web of Science ®Google Scholar
• Thomas P. E., Bandiera S., Maines S. L., Ryan D. E., Levin W. Regulation of cytochrome P-450j, a high-affinity N-nitrosodimethylamine de-methylase, in rat hepatic microsomes. Biochemistry 1987; 26: 2280
   PubMed Web of Science ®Google Scholar
• Song B. J., Gelboin H. V., Park S. S., Yang C. S., Gonzalez F. J. Complementary DNA and protein sequences of ethanol-inducible rat and human cytochrome P-450s. J. Biol. Chem. 1986; 261: 16689
   PubMed Web of Science ®Google Scholar
• Perrot N., Nalpas B., Yang C. S., Beaune P. H. Modulation of cytochrome P450 isozymes in human liver, by ethanol and drug intake. Eur. J. Clin. Invest. 1989; 19: 549
   PubMed Web of Science ®Google Scholar
• Porter T. D., Khani S. C., Coon M. J. Induction and tissue-specific expression of rabbit cytochrome P450IIE1 and IIE2 genes. Mol. Pharmacol. 1989; 36: 61
   PubMed Web of Science ®Google Scholar
• Peng H. M., Porter T. D., Ding X., Coon M. J. Differences in the developmental expression of rabbit cytochromes P-450 2E1 and 2E2. Mol. Pharmacol. 1991; 40: 58
   PubMedGoogle Scholar
• Watkins P. B. Role of cytochromes P450 in drug metabolism and hepatotoxicity. Semin. Liv. Dis. 1990; 10: 235
   PubMed Web of Science ®Google Scholar
• Hardwick J. P., Gonzalez F. J., Kasper C. B. Cloning of DNA complementary to cytochrome P-450 induced by pregnenolone-16a-carbon-itrile. J. Biol. Chem. 1983; 258: 10182
   PubMedGoogle Scholar
• Gonzalez F. J., Song B. J., Hardwick J. P. Pregnenolone 16a-carbonitrile-inducible P-450 gene family: gene conversion and differential regulation. Mol. Cell. Biol 1986; 6: 2969
   PubMed Web of Science ®Google Scholar
• Hostetler K. A., Wrighton S. A., Kremers P., Guzelian P. S. Immunochemical evidence for multiple steroid-inducible hepatic cytochromes P-450 in the rat. Biochemistry 1987; 245: 27
   Google Scholar
• Graves P. E., Kaminsky L. S., Halpert J. Evidence for functional and structural multiplicity of pregnenolone-16a-carbonitrile-inducible cytochrome P-450 isozymes in rat liver microsomes. Biochemistry 1987; 26: 3887
   PubMed Web of Science ®Google Scholar
• Halpert J. R. Multiplicity of steroid-inducible cytochromes P-450 in rat liver microsomes. Arch. Biochem. Biophys. 1988; 263: 59
   PubMed Web of Science ®Google Scholar
• Wrighton S. A., Maurel P., Schuetz E. G., Watkins P. B., Young B., Guzelian P. S. Identification of the cytochrome P-450 induced by macrolide antibiotics in rat liver as the glucocorticoid responsive cytochrome P-450p. Biochemistry 1985; 24: 2171
   PubMed Web of Science ®Google Scholar
• Sonderfan A. J., Arlotto M. P., Dutton D. R., McMillen S. K., Parkinson A. Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450. Arch. Biochem. Biophys. 1987; 255: 27
   PubMed Web of Science ®Google Scholar
• Wang P. P., Beaune P., Kaminsky L. S., Dannan G. A., Kadlubar F. F., Larrey D., Guengerich F. P. Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes. Biochemistry 1983; 22: 5375
   PubMed Web of Science ®Google Scholar
• Watkins P. B., Wrighton S. A., Maurel P., Schuetz E. G., Mendez-Picon G., Parker G. A., Guzelian P. S. Identification of an inducible form of cytochrome P-450 in human liver. Proc. Natl. Acad. Sci. U.S.A. 1985; 82: 6310
   PubMed Web of Science ®Google Scholar
• Guengerich F. P., Martin M. V., Beaune P. H., Kremers P., Wolff T., Waxman D. J. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 1986; 262: 5051
   Google Scholar
• Beaune P., Kremers P., Letawa-Goujon F., Gielen J. E. Monoclonal antibodies against human liver cytochrome P-450. Biochem. Pharmacol. 1985; 34: 3547
   PubMed Web of Science ®Google Scholar
• Molowa D. T., Schuetz E. G., Wrighton S. A., Watkins P. B., Kremers P., Mendez-Picon G., Parker G. A., Guzelian P. S. Complete cDNA sequence of a cytochrome P-450 inducible by glucocorticoids in human liver. Proc. Natl. Acad. Sci. U.S.A. 1986; 83: 5311
   PubMed Web of Science ®Google Scholar
• Beaune P. H., Umbenhauer D. R., Bork R. W., Lloyd R. S., Guengerich F. P. Isolation and sequence determination of a cDNA clone related to human cytochrome P-450 nifedipine oxidase. Proc. Natl. Acad. Sci. U.S.A. 1986; 83: 8064
   PubMed Web of Science ®Google Scholar
• Gonzalez F. J., Schmid B. J., Umeno M., McBride O. W., Hardwick J. P., Meyer U. A., Gelboin H. V., Idle J. R. Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. DNA 1988; 7: 79
   PubMedGoogle Scholar
• Bork R. W., Muto T., Beaune P. H., Srivastava P. K., Lloyd R. S., Guengerich F. P. Characterization of mRNA species related to human liver cytochrome P-450 nifedipine oxidase and the regulation of catalytic activity. J. Biol. Chem. 1989; 264: 910
   PubMed Web of Science ®Google Scholar
• Waxman D. J., Attisano C., Guengerich F. P., Lapenson D. P. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 66-hydroxylase cytochrome P-450 enzyme. Arch. Biochem. Biophys. 1988; 263: 424
   PubMed Web of Science ®Google Scholar
• Kitada M., Kamataki T., Itahashio K., Rikihisa T., Kanakubo Y. P-450 HFLa, a form of cytochrome P-450 purified from human fetal livers, is the 16ot-hydroxylase of dehydroepiandrosterone 3-sulfate. J. Biol. Chem. 1987; 262: 13534
   PubMed Web of Science ®Google Scholar
• Bocker R. H., Guengerich F. P. Oxidation of 4-aryl- and 4-alkyl-substituted 2,6-dimethyl-3,5, bis(alkoxycarbonyl)-l, 4-dihydropyridines by human liver microsomes and immunochemical evidence for the involvement of a form of cytochrome P-450. J. Med. Chem. 1986; 29: 1596
   PubMed Web of Science ®Google Scholar
• Kronbach T., Fischer V., Meyer U. A. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporin with other drugs. Clin. Pharmacol. Ther. 1988; 43: 630
   PubMed Web of Science ®Google Scholar
• Imaoka S., Enomoto K., Oda Y., Asada A., Fujimori M., Shimada T., Fujita S., Guengerich F. P., Funae Y. Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: comparison of those with rat hepatic cytochrome P-450s. J. Pharm. Exp. Ther. 1990; 255: 1385
   PubMed Web of Science ®Google Scholar
• Ramsdell H. S., Parkinson A., Eddy A. C., Eaton D. L. Bioactivation of aflatoxin B, by human liver microsomes: role of cytochrome P450 IIIA enzymes. Toxicol. Appl. Pharmacol. 1991; 108: 436
   PubMed Web of Science ®Google Scholar
• Guengerich F. P., Miiller-Enoch D., Blair I. A. Oxidation of quinidine by human liver cytochrome P-450. Mol. Pharmacol. 1986; 30: 287
   PubMed Web of Science ®Google Scholar
• Guengerich F. P. Oxidation of 17a-ethynylestra-diol by human liver cytochrome P-450. Mol. Pharmacol. 1988; 33: 500
   PubMed Web of Science ®Google Scholar
• Kronbach T., Mathys D., Umeno M., Gonzalez F. J., Meyer U. A. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol. Pharmacol. 1989; 36: 89
   PubMed Web of Science ®Google Scholar
• Miranda C. L., Reed R. L., Guengerich F. P., Buhler D. R. Role of cytochrome P450IIIA4 in the metabolism of the pyrrolizidine alkaloid se-necionine in human liver. Carcinogenesis 1991; 12: 515
   PubMed Web of Science ®Google Scholar
• Wang R. A., Kari P. H., Lu A. Y.H., Thomas P. E., Guengerich F. P., Vyas K. P. Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch. Biochem. Biophys. 1991; 290: 355
   PubMed Web of Science ®Google Scholar
• Guengerich F. P. Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem. Res. Toxicol. 1990; 3: 363
   PubMed Web of Science ®Google Scholar
• Watkins P. B., Murray S. A., Winkelman L. G., Heuman D. M., Wrighton S. A., Guzelian P. S. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. J. Clin. Invest. 1989; 83: 688
   PubMed Web of Science ®Google Scholar
• Saenger P., Forster E., Kream J. 6b˜-Hy-droxycortisol: a noninvasive indicator of enzyme induction. J. Clin. Endocrinol. Metab. 1981; 52: 381
   PubMedGoogle Scholar
• Oellerich M., Burdelski M., Lautz H. U., Schulz M., Schmidt F. W., Herrmann H. Lidocaine metabolite formation as a measure of liver function in patients with cirrhosis. Ther. Drug Monit. 1990; 12: 219
   PubMedGoogle Scholar
• Wrighton S. A., Brian W. R., Sari M. A., Iwasaki M., Guengerich F. P., Raucy J. L., Molowa D. T., VandenBranden M. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol. 1990; 38: 207
   PubMed Web of Science ®Google Scholar
• Aoyama T., Yamano S., Waxman D. J., Lapenson D. P., Meyer U. A., Fischer V., Tyndale R., Inaba T., Kalow W., Gelboin H. V., Gonzalez F. J. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. J. Biol. Chem. 1989; 264: 10388
   PubMed Web of Science ®Google Scholar
• Schuetz J. D., Molowa D. T., Guzelian P. S. Characterization of a cDNA encoding a new member of the glucocorticoid-responsive cytochromes P450 in human liver. Arch. Biochem. Biophys. 1989; 274: 355
   PubMed Web of Science ®Google Scholar
• Rane A., Sjoqvist F., Orrenius S. Drugs and fetal metabolism. Clin. Pharmacol. Ther. 1973; 14: 666
   PubMed Web of Science ®Google Scholar
• Cresteil T., Beaune P., Kremers P., Flinois J. P., Leroux J. P. Drug-metabolizing enzymes in human foetal liver: partial resolution of multiple cytochromes P-450. Pediatr. Pharmacol. 1982; 2: 199
   PubMedGoogle Scholar
• Wrighton S. A., Molowa D. T., Guzelian P. S. Identification of a cytochrome P-450 in human fetal liver related to glucorcorticoid-inducible cytochrome P-450HLp in the adult. Biochem. Pharmacol. 1988; 37: 3053
   PubMed Web of Science ®Google Scholar
• Wrighton S. A., VandenBranden M. Isolation and characterization of human fetal liver cytochrome P450HLp2: a third member of the P450III gene family. Arch. Biochem. Biophys. 1989; 268: 144
   PubMed Web of Science ®Google Scholar
• Kitada M., Kamataki T., Itahashi K., Rikihisa T., Kato R., Kanakurbo Y. Purification and properties of cytochrome P-450 from homogenates of human fetal livers. Arch. Biochem. Biophys. 1985; 241: 275
   PubMed Web of Science ®Google Scholar
• Hulla J. E., Juchau M. R. Occurrence and inducibility of cytochrome P450IIIA in maternal and fetal rats during prenatal development. Biochemistry 1989; 28: 4871
   PubMedGoogle Scholar
• Kitada M., Taneda M., Itahashi K., Kamataki T. Four forms of cytochrome P-450 in human fetal liver: purification and their capacity to activate promutagens.y. Cancer Res. 1991; 82: 426
   Google Scholar
• Eberhart D. C., Gemzik B., Halvorson M. R., Parkinson A. Species differences in the toxicity and cytochrome P450 IIIA-dependent metabolism of digitoxin. Mol. Pharmacol. 1991; 40: 859
   PubMed Web of Science ®Google Scholar
• Wrighton S. A., Stevens J. C., unpublished observations
   Google Scholar